Source-grounded facts extracted from TransMedics Group, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
TransMedics Group, Inc. reported the quarter ended March 31, 2026 results: revenue $173.9 million, net income $7.3 million, EPS $0.20 per fully diluted share. Guidance reaffirmed.
“Total revenue of $173.9 million in the first quarter of 2026, a 21% increase compared to the first quarter of 2025 ▪ Net income of $7.3 million or $0.20 per fully diluted share in the first quarter of 2026”
TransMedics Group, Inc. entered into Lease with BioMed Realty valued at approximately $23.9 million (effective 2026-01-08).
“On January 8, 2026, TransMedics Group, Inc. (the “Company”) entered into a lease agreement (the “Lease”) with BioMed Realty (the “Landlord”) for the lease of approximately 498,286 square feet of space located at 188 Assembly Park Drive, Somerville, MA 02145 (the “Premises”)”
TransMedics Group, Inc. completed an acquisition involving Teaghlach Aviation, LLC for approximately $14.5 million (closed 2025-10-03).
“on October 3, 2025, the Buyer acquired a fixed-wing aircraft from Teaghlach Aviation, LLC for a purchase price of approximately $14.5 million”
TransMedics Group, Inc. reported quarter ended March 31, 2024 results: revenue $96.9 million, net income $12.2 million, EPS $0.35 per fully diluted share. Guidance raised.
“Net revenue of $96.9 million in the first quarter of 2024, a 133% increase compared to the first quarter of 2023”
TransMedics Group, Inc. completed an acquisition involving Evans General Aviation, LLC for approximately $12.5 million (closed 2024-03-08).
“on March 8, 2024, the Buyer acquired a fixed-wing aircraft from Evans General Aviation, LLC for a purchase price of approximately $12.5 million (together with the Prior Acquisitions, the “Acquisitions”).”
TransMedics Group, Inc. reported full-year 2024 results: revenue $360 million to $370 million. Guidance initiated.
“TransMedics expects total revenue for full-year 2024 to be in the range of $360 million to $370 million, which represents 49% to 53% growth compared to the company’s prior year revenue.”
TransMedics Group, Inc. reported the year ended December 31, 2023 results: revenue $241.6 million, net income $(25.0) million.
“December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the full year of 2022 ▪ Generated net income of $4.0 million or $0.12 per share in the fourth quarter of 2023 “2023 was a”
TransMedics Group, Inc. reported the quarter ended December 31, 2023 results: revenue $81.2 million, net income $4.0 million, EPS $0.12 per share.
“patients with end-stage lung, heart, and liver failure, today reported financial results for the quarter and year ended December 31, 2023. Recent Highlights ▪ Total revenue of $81.2 million in the fourth quarter of 2023, a 159% increase compared to the fourth quarter of 2022 ▪ Total revenue of $241.6 million in the full year of 2023, a 159% increase compared to the”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.